[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538004":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":28,"responsibleParty":47,"collaborators":49,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort of patients with mold invasive fungal infection",null,"Patients \\>18 y, with a diagnosis of proven or probable mold invasive fungal infection (Aspergillus, Mucorales, Fusarium or Scedosporium), according to modified 2019 EORTC\u002FMGS criteria, at diagnosis or at a refractory state after a first-line antifungal treatment",[13],{"name":14,"affiliation":15,"role":16},"Fanny LANTERNIER, MD, PhD","APHP","STUDY_CHAIR",[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Alexandra SERRIS, MD, PhD","CONTACT","06 68 80 24 92","+33","alexandra.serris@aphp.fr",{"name":25,"role":20,"phone":26,"phoneExt":22,"email":27},"Gael PLASTOW, Project advisor","01 44 38 18 57","gael.plastow@aphp.fr",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Hôpital Necker Enfants Malades","RECRUITING","Paris","75015","France","FR",{"type":37,"coordinates":38},"Point",[39,40],2.3488,48.85341,{"lat":40,"lon":39},[43,44,45],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},{"name":25,"role":20,"phone":26,"phoneExt":22,"email":10},{"name":14,"role":46,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[50],{"name":51,"class":6},"URC-CIC Paris Descartes Necker Cochin","100538004","immunomonitoring-of-mold-invasive-infections-100538004",false,"NCT06285188","Immunomonitoring of Mold Invasive Infections","IMMUNOFIL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium\n* Proven or probable according to 2019 EORTC\u002FMGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria\n* Within 14 days of IFD diagnosis or\n* a refractory state defined by the 2009 MGS\u002FEORT failure criteria (clinical, radiological, or microbiological failure) of a first-line antifungal treatment leading to a change of therapy by the attending physician of the patient\n* Patients with aspergillosis or mucormycosis for whom ELISPOTs are developed: Total lymphocyte count \\> 700\u002Fmm3 on the last sample taken\n* No opposition to participate to the research\n* Affiliated or beneficiary of social security system\n\nExclusion Criteria:\n\n* Bacterial co-infection in the last 14 days\n* Previous treatment with anti-PD1 antibodies","ALL","18 Years",{"count":62,"type":63},20,"ESTIMATED","OBSERVATIONAL","Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.",[67,68],"Invasive Fungal Disease","Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium",[70,71,72,73],"Invasive fungal diseases,","adaptative immunity against filamentous fungi","immune checkpoint molecules","anti-PD1","2025-11-17",{"date":76,"type":77},"2025-11-20","ACTUAL",{"date":79,"type":77},"2025-07-28",{"date":81,"type":63},"2027-07",{"name":5,"class":6},1]